Crohn´s disease is an independent risk factor for liver fibrosis in patients with inflammatory bowel disease and non-alcoholic fatty liver disease
- PMID: 37872034
- DOI: 10.1016/j.ejim.2023.10.019
Crohn´s disease is an independent risk factor for liver fibrosis in patients with inflammatory bowel disease and non-alcoholic fatty liver disease
Abstract
Background and aims: Controversial data have been reported regarding the prevalence of Non-Alcoholic Fatty Liver Disease (NAFLD) in Inflammatory Bowel Disease (IBD) population and IBD-related risk factors. The aim of the study was to assess the prevalence and risk factors associated with NAFLD and liver fibrosis in IBD participants compared with non-IBD controls.
Methods: Cross-sectional, case-control study including 741 IBD cases and 170 non-IBD controls, matched by sex and age. All participants underwent liver ultrasound, transient elastography and laboratory tests. A logistic regression multivariable analysis was performed adjusting for classic metabolic risk factors and history of systemic steroid use.
Results: The prevalence of NAFLD and significant liver fibrosis was 45 % and 10 % in IBD group, and 40 % and 2.9 % in non-IBD group (p = 0.255 and 0.062, respectively). Longer IBD duration (aOR 1.02 95% CI (1.001-1.04)) and older age at IBD diagnosis (aOR 1.02 95 % CI (1.001-1.04)) were independent risk factors for NAFLD in IBD group. Crohn´s Disease was an independent risk factor for significant liver fibrosis in participants with IBD and NAFLD (aOR 3.97 95 % CI (1.78-8.96)). NAFLD occurred at lower BMI levels in IBD group with NAFLD compared to non-IBD group with NAFLD (aOR 0.92 95 % CI (0.87-0.98)).
Conclusions: Although we found no differences in the prevalence of NAFLD and liver fibrosis between IBD group and non-IBD group, our findings suggest that liver fibrosis progression should be closely monitored in patients with concomitant CD and NAFLD, more in particular in those with long standing active disease.
Keywords: Inflammatory bowel disease; Liver fibrosis; NAFLD.
Copyright © 2023 European Federation of Internal Medicine. Published by Elsevier B.V. All rights reserved.
Conflict of interest statement
Declaration of Competing Interest The authors declare that there is no conflict of interest regarding this project.
Similar articles
-
Inflammatory Bowel Disease Is an Independent Risk Factor for Metabolic Dysfunction-Associated Steatotic Liver Disease in Lean Individuals.Inflamm Bowel Dis. 2024 Aug 1;30(8):1274-1283. doi: 10.1093/ibd/izad175. Inflamm Bowel Dis. 2024. PMID: 37607330 Free PMC article.
-
Nonalcoholic fatty liver disease in patients with inflammatory bowel disease: Beyond the natural history.World J Gastroenterol. 2019 Oct 7;25(37):5676-5686. doi: 10.3748/wjg.v25.i37.5676. World J Gastroenterol. 2019. PMID: 31602167 Free PMC article.
-
Screening for Nonalcoholic Fatty Liver Disease in Inflammatory Bowel Diseases: A Cohort Study Using Transient Elastography.Inflamm Bowel Dis. 2019 Jan 1;25(1):124-133. doi: 10.1093/ibd/izy200. Inflamm Bowel Dis. 2019. PMID: 29889226
-
Liver Fibrosis in Non-Alcoholic Fatty Liver Disease and Progression to Hepatocellular Carcinoma in Patients with Inflammatory Bowel Disease: A Systematic Review.Cancers (Basel). 2023 Jun 27;15(13):3367. doi: 10.3390/cancers15133367. Cancers (Basel). 2023. PMID: 37444477 Free PMC article. Review.
-
Systematic Review With Meta-analysis: Epidemiology of Nonalcoholic Fatty Liver Disease in Patients With Inflammatory Bowel Disease.Inflamm Bowel Dis. 2019 Oct 18;25(11):1764-1772. doi: 10.1093/ibd/izz043. Inflamm Bowel Dis. 2019. PMID: 30918952
Cited by
-
A Study of Dizziness or Vertigo Cases Associated with Inflammatory Bowel Disease (Crohn's Disease and Ulcerative Colitis) in a Vertigo Outpatient Clinic.J Clin Med. 2025 Jan 8;14(2):341. doi: 10.3390/jcm14020341. J Clin Med. 2025. PMID: 39860349 Free PMC article.
-
Heavy arch: from inflammatory bowel diseases to metabolic disorders.Gut. 2024 Jul 11;73(8):1376-1387. doi: 10.1136/gutjnl-2024-331914. Gut. 2024. PMID: 38777571 Free PMC article. Review.
-
MASLD and liver fibrosis in patients with psoriasis receiving IL-17 or IL-23 inhibitors: a systematic review.Therap Adv Gastroenterol. 2025 May 22;18:17562848251335824. doi: 10.1177/17562848251335824. eCollection 2025. Therap Adv Gastroenterol. 2025. PMID: 40417712 Free PMC article. Review.
-
Cardiometabolic diseases in patients with inflammatory bowel disease: An evidence-based review.World J Gastroenterol. 2025 Jun 28;31(24):107661. doi: 10.3748/wjg.v31.i24.107661. World J Gastroenterol. 2025. PMID: 40599191 Free PMC article. Review.
-
Hepatobiliary manifestations of inflammatory bowel disease in Saudi Arabia: A retrospective analysis.Saudi Med J. 2025 Jan;46(1):52-58. doi: 10.15537/smj.2025.46.1.20240758. Saudi Med J. 2025. PMID: 39779365 Free PMC article.
MeSH terms
LinkOut - more resources
Full Text Sources
Medical